Endogenous IL-33/ST2 signaling enhances tumor-infiltrating ILC2s and CD8+ T cell-mediated cancer immunity in pancreatic ductal adenocarcinoma-bearing mouse models [118]. This evidence concerns the gene IL33 and cancer.